Bronchospasmolytika und Antiasthmatika

Zusammenfassung

Bronchospasmolytika werden zur Behandlung des Asthma bronchiale und der chronisch-obstruktiven Lungenkrankheit (COPD) eingesetzt. Bei beiden Erkrankungen ist es das Ziel, die Bronchialobstruktion, die beim Asthma besser reversibel ist als bei der COPD, zu reduzieren. Im Spätstadium der COPD mit Ateminsuffizienz, Emphysem und Cor pulmonale sollen die Symptome so weit wie möglich gebessert werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alagha K, Palot A, Sofalvi T, Pahus L, Goultra M, Tummino C, Martinez S, Charpin D, Bourdin A, Chanez P (2014): Long-acting muscarinic antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis 5: 85–98Google Scholar
  2. Barnes PJ (2008): Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8: 183–192Google Scholar
  3. Barnes P (2012): Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol 129: 48–59Google Scholar
  4. Barnes PJ (2015): Therapeutic approaches to asthma–chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol 136:531-545Google Scholar
  5. Befekadu E, Onofrei C, Collice GL (2014): Tiotropium in asthma: a systematic review. J Asthma Allergy 7: 11–21Google Scholar
  6. Brand PL (2011): Inhaled corticosteroids should be the first line of treatment for children with asthma. Paediatr Respir Rev 12: 245–249Google Scholar
  7. Buhl R (2008): Atemwegserkrankungen: Moderne Therapiekonzepte für adäquate Behandlungsstrategien. J Pharmakol Ther 17: 95Google Scholar
  8. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (1998): Arzneimittel mit problematischer Bioverfügbarkeit. 9. Bekanntmachung gemäß §26, Abs. 3 AMG vom 19.1.1998Google Scholar
  9. Bundesministerium für Gesundheit (2014): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) und Anlage IX – Festbetragsgruppenbildung Beta2-Sympathomimetika, inhalativ oral, Gruppe 1, in Stufe 2 nach § 35a Absatz 3 in Verbindung mit Absatz 4 Satz 1 SGB V vom 17. Juli 2014, veröffentlicht am Montag, 11. August 2014 BAnz AT 11.08.2014 B3Google Scholar
  10. Bundesministerium für Gesundheit (2016): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Aclidiniumbromid vom 7.4.2016 veröffentlicht am 7. April 2016, BAnz AT 03.05.2016 B3Google Scholar
  11. Cates CJ, Cates MJ (2008): Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev, July 16: CD006363Google Scholar
  12. Chauhan BF, Chartrand C, Ducharme FM (2013a): Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. Issue 2, Art. No. CD009611Google Scholar
  13. Chauhan BF, Ben Salah R, Ducharme FM (2013b): Addition of anti-leukotriene agents to inhaled cortocosteroids in children with persisten asthma. Cochrane Database Syst Rev doi:  10.1002/14651858.CD009585.pub2
  14. Cingi C, Mulik NB, Ipci K, Sahin E (2015): Antileukotrienes in upper airway inflammatory disease. Curr Allergy Asthma Rep 15:64. Doi:  10.1007/s11882-015-0564-7
  15. EMA Press Release (2010): Asthma treatment (long and short-acting Beta agoniststs and anticholinergics): risk of myocardial ischaemia and long-term safety, especially in children. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/07/WC500094267.pdf
  16. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups (2009): Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374: 695–703Google Scholar
  17. FDA Press Release (2010): FDA announces new safety controls for long-acting beta agonists, medications used to treat asthma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200931.htm
  18. FDA Press Release (2011): FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs). Internet: http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm. Update 8.1.2016
  19. Fuhlbrigge AL, Kelly HW (2014): Inhaled corticosteroids in children: effects on bone mineral density and growth. Lancet Respir Med 2: 487-496Google Scholar
  20. Gibb A, Yang LPH (2013): Oldaterol: first global approval. Drugs 73:1842–1846Google Scholar
  21. Gibson PG, McDonald VM (2015): Asthma-COPD overlap 2015: now were are six. Thorax 70: 683–691Google Scholar
  22. Gillissen A, Berdel D, Buhl R et al (2007): β2-Sympathomimetika: Gefahren in der Asthmatherapie? Lehren aus der SMART1-Studie. Dtsch Med Wochenschr 132: 33–39Google Scholar
  23. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from: http://www.goldcopd.org
  24. Haasler I, Buhl R, Taube C (2011): Asthma bronchiale: neue Erkenntnisse und Entwicklungen. Dtsch Med Wochenschr 136: 198–200Google Scholar
  25. Hines KL, Peebles RS (2017): Management of the asthma-COPD overlap syndrome (ACOS): a review of the evidence. Curr Allergy Asthma Rep 17:doi:  10.1007/s11882-017-0683-4
  26. Hizawa N (2016): Clinical approaches towards asthma and chronic obstructive pulmonary disease based on the heterogeneity of disease pathogenesis. Clin Experimental Allergy 46: 679–687Google Scholar
  27. Kirsch F, Teuner CM, Menn P, Leidl R (2013): Krankheitskosten für Asthma und COPD bei Erwachsenen in der Bundesrepublik Deutschland. Gesundheitswesen 75: 413–423Google Scholar
  28. Kuehn BM (2009): FDA panel: ban 2 popular asthma drugs. JAMA 301: 365–366Google Scholar
  29. Küpper T, Goebbels K, Kennes LN, Netzer NC (2012): Cromoglycate, reproterol, or both--what‘s best for exercise-induced asthma? Sleep Breath 16: 1229–1235Google Scholar
  30. Lange P, Halpin DM, O’Donnell DE, MacNee W (2016): Diagnosis assessment, and phenotyping of COPD: beyond FEV1. Int J COPD 11: 3–12Google Scholar
  31. Lemmer B (1990): Chronopharmakologische Aspekte der Theophyllintherapie. In: Blume H (Hrsg.): Bioäquivalenz retardierter Theophyllin-Fertigarzneimittel. Govi, Frankfurt, S. 75–82Google Scholar
  32. Levenson M (2008): Long-Acting Beta-Agonists and Adverse Asthma Events Meta-Analysis. Statistical Briefing Package for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee on December 10–11, 2008. Internet: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf
  33. McNicholas WT (2017): COPD-OSA overlap syndrome: evolving evidence regarding epidemioloygy, clinical consequence, and management. Chest: doi:10.10167J-CHSET 2017.04.160Google Scholar
  34. Meyer N, Nuss SJ, Rothe T, Siebenhüner A, Akdis CA, Menz G (2014): Differential serum protein markers and the clinical severity of asthma. J Asthma Allergy 7: 67–75Google Scholar
  35. National Institutes of Health, National Heart Lung and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. NIH Publication No 07-4051 2007, http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
  36. Nationale Versorgungsleitlinie Asthma, Version 5 (2013). Internet: http://www.versorgungsleitlinien.de/themen/asthma/pdf/nvl-asthma-2aufl.-lang-5.pdf
  37. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group (2006): The salmeterol multicenter asthma research trial: a comparison of unusual pharmacotherapy for asthma or usual pharmacology plus salmeterol. Chest 129: 15–26Google Scholar
  38. Ngkelo A, Adcock IM (2013): New Treatment for COPD. Current Opinion Pharmacology. 13: 1–8Google Scholar
  39. Nguyen M-H (2015): Olodaterol – Lang wirksamer Beta-2-Adrenozeptor-Agonist zur Dauertherapie bei chronisch obstruktiver Lungenerkrankung (COPD). Arzneimitteltherapie 33: 417-419Google Scholar
  40. Normansell R, Walker S, Milan SJ, Walters E, Nair P (2014): Omazilumab for chronoc asthma in adults and children. Coch rane Collaboration DOI:  10.1002/14651858.CD003559.pub4
  41. Oba Y, Lone NA (2013): Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 7: 13–24Google Scholar
  42. O‘Reilly DA, Awale A, Cartledge P (2015): Question 2: Blast from the past: is oral salbutamol useful in resource-poor settings? Arch Dis Child 100: 806–809Google Scholar
  43. Patel M, Pilcher JJ, Pritchard A, Perrin K, Travers J, Shaw D, Holt S, Harwood M, Black P, Weatherhall M, Beasley R, for the SMART Study Group (2013): Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 1: 32–42Google Scholar
  44. Pedersen S (2006): Clinical safty of inhaled corticosteroids for asthma in children – an update of long-term trials. Drug Safety 29: 599–612Google Scholar
  45. Rank MA, Hagan JB, Park MA, Podjasek JC, Samant SA, Volcheck GW, Erwin PJ, West CP (2013): The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 131: 724–729Google Scholar
  46. Rennard SI, Drummond MB (2015): Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet 385:1778–1788Google Scholar
  47. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA (2009): Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review with meta-analysis. Respir Med 103: 1421–1429Google Scholar
  48. Schmidt H (1994): Retardtheophyllin ist nicht gleich Retardtheophyllin. Atemwegs-Lungenkr 20: 223–231Google Scholar
  49. Singh S, Loke YK, Furberg CD (2008): Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300: 1439–1450Google Scholar
  50. Smolensky M, Lemmer B, Reinberg A (2007): The chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Del Rev 59: 852–882Google Scholar
  51. Tashkin DP, Celli B, Senn S, Burkhadt D, Kesten S, Menjoge S, Decramer M (2008): A 4-year trial of tiotropium in chronic pulmonary disease. N Engl J Med 359: 1543–1554Google Scholar
  52. Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S (2012): Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD 9: 289–296Google Scholar
  53. Watts KL, Chavasse RJ (2012): Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev. May, 16; 5: CD006100Google Scholar
  54. Woodruff PG, Augusti A, Roche N, Singh D, Martinez FJ (2015): Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 385: 1789–1798Google Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Fakultät für Klinische Medizin Mannheim der Universität HeidelberInstitut für Pharmakologie und ToxikologieMannheimDeutschland

Personalised recommendations